This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Telik Announces Reverse Split Of Common Stock

PALO ALTO, Calif., March, 30, 2012 /PRNewswire/ -- Telik, Inc. (NASDAQ: TELK) today announced a 1-for-30 reverse split of its common stock.  Telik's common stock will begin trading on a post-split basis on the NASDAQ Capital Market on April 2, 2012.  The reverse split is expected to enable the Company to meet the $1.00 minimum bid price required for continued listing on the NASDAQ Capital Market. 

At the effective time of the reverse split, every 30 shares of the Company's pre-split common stock, including shares subject to outstanding stock options and shares available for grant under the Company's stock options plans, will automatically be combined into one share of the Company's post-split capital stock.  The reverse split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage, except that stockholders will receive cash in lieu of any fractional shares based on today's closing price on NASDAQ.  The Company's transfer agent will provide instructions to stockholders regarding the process for exchanging shares.  Upon completion of the reverse split, there will be approximately 1,816,376 shares of Telik's common stock outstanding.  Additional information regarding the reverse split can be found in Telik's definitive proxy statement filed with the Securities and Exchange Commission on March 5, 2012.  The Company today filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect the reverse split.

In addition, the Company expects to undertake a re-alignment of its spending priorities, focusing on the clinical development of its lead product candidate, Telintra®, and reducing annual operating expenses by approximately $2.5 million over the Company's February guidance of $12 to $13 million for 2012.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated drug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.  Additional information is available at .

Forward Looking Statements

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,846.27 +69.84 0.42%
S&P 500 1,981.42 -5.63 -0.28%
NASDAQ 4,745.3440 -35.92 -0.75%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs